ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in
ScripCanadian specialty firm Aralez Pharmaceuticals Inc. is confident that its heart attack and stroke-prevention combination product Yosprala will gain FDA approval on a third review, but that will
Pink SheetAralez Pharmaceuticals Inc. ’s new CEO Adrian Adams offered a glimpse at his plans for the new pharmaceutical company Aralez Pharmaceuticals , which will be formed later this year out of the merger